首页 / 专利分类库 / 有机化学 / 无环或碳环化合物 / 含有至少具有1个氮-氮重键的至少两个氮原子的链的化合物
序号 专利名 申请号 申请日 公开(公告)号 公开(公告)日 发明人
41 METHODS AND COMPOSITIONS FOR IDENTIFYING METHYLATED CYTOSINES PCT/US2022074999 2022-08-16 WO2023023500A1 2023-02-23 BROWN COLIN; LIU XIAOHAI; WU XIAOLIN; BRUSTAD ERIC; SHULTZABERGER SARAH E
Disclosed herein include methods, compositions, reaction mixtures, kits and systems for identification of methylated cytosines in nucleic acids using a bisulfite-free, one-step chemoenzymatic modification of methylated cytosines.
42 ACILHIDRAZONAS PARA EL TRATAMIENTO DE ENFERMEDADES NEUROLÓGICAS PCT/ES2019/070649 2019-09-27 WO2020065119A1 2020-04-02 PÉREZ FERNÁNDEZ, Ruth; CANAL MARTÍN, Andrea; SANCHEZ BARRENA, María José; MANSILLA APARICIO, Alicia

La presente invención se refiere a un grupo de compuestos con un núcleo estructural de acilhidrazona que presentan capacidad moduladora de la interacción entre las proteínas NCS-1 y Ric8a, implicadas en el proceso de regulación del número de sinapsis y la probabilidad de liberación de neurotransmisores.Estos compuestos, por tanto, son útiles para el tratamiento de enfermedades neurológicas en las que está afectado el número de sinapsis, tales como enfermedad de Alzheimer, enfermedad de Huntington o enfermedad de Parkinson.

43 TUNABLE NITRIC OXIDE-RELEASING MACROMOLECULES HAVING MULTIPLE NITRIC OXIDE DONOR STRUCTURES PCT/US2012/052350 2012-08-24 WO2013029009A1 2013-02-28 SCHOENFISCH, Mark; LU, Yuan; STASKO, Nathan; BAO, Jian

Provided here are nitric oxide-releasing compounds that include at least two different NO donor functional groups of the same class. In some embodiments, such nitric oxide-releasing compounds are macromolecules such as dendrimer and co-condensed silica. Pharmaceutical compositions, wound dressings, kits and methods of treatments are also provided herein.

44 POLYMER SUPPORTED REAGENTS AND METHODS OF REDUCING AROMATIC NITRO COMPOUNDS BY USING THE SAME PCT/KR2012001928 2012-03-16 WO2012128515A3 2013-02-07 HAN YANG-KYOO; CHO JIN; LEE SANG-MI; SHIN SEUNG-HOON
The present invention relates to a polymer supported reagent comprising a novel crosslinked mesoporous polymer, enabling a simple and easy production of an azoxy compound or an azo compound from an aromatic nitro compound, and a method of selectively reducing an aromatic nitro compound by using the same. The polymer supported reagent comprises a certain acrylamide mesoporous crosslinked polymer.
45 POLYMER SUPPORTED REAGENTS AND METHODS OF REDUCING AROMATIC NITRO COMPOUNDS BY USING THE SAME PCT/KR2012/001928 2012-03-16 WO2012128515A2 2012-09-27 HAN, Yang-Kyoo; CHO, Jin; LEE, Sang-Mi; SHIN, Seung-Hoon

The present invention relates to a polymer supported reagent comprising a novel crosslinked mesoporous polymer, enabling a simple and easy production of an azoxy compound or an azo compound from an aromatic nitro compound, and a method of selectively reducing an aromatic nitro compound by using the same. The polymer supported reagent comprises a certain acrylamide mesoporous crosslinked polymer.

46 METHOD FOR SORTING CARBON NANOTUBES (CNTS) AND DEVICE FOR CNTS SORTING PCT/KR2010/007781 2010-11-05 WO2011062388A1 2011-05-26 LEE, Kwangyeol

A method for sorting carbon nanotubes (CNTs) is disclosed. In one embodiment, a method for sorting CNTs of the present disclosure comprises providing to a surface of a substrate, the surface modified with a trans isomer of photo-isomerization-reactive diazo compound, a dispersion containing a mixture of conducting CNTs and semiconducting CNTs removing CNTs which are not associated with the modified surface from the surface; and irradiating the modified surface to detach the CNTs associated with the modified surface.

47 FLUORESCENT XANTHENES AND WHITE LIGHT FLUOROPHORES PCT/US2007/073864 2007-07-19 WO2008011508A1 2008-01-24 STRONGIN, Robert, M.; WARNER, Isiah, M.; YANG, Youjun; LOWRY, Mark; FAKAYODE, Sayo, O.; ESCOBEDO CORDOVA, Jorge, O.; XU, Xiangyang

Xanthene compounds are disclosed having fluorescence at multiple wavelengths. Also disclosed are methods for their synthesis and use. Some of the compounds fluoresce at three wavelengths, emitting white light. Uses include the imaging of biological tissues, illumination, and display technologies. Many of the compounds have large Stokes shifts, and are resistant to photobleaching. The fluorescence may be readily distinguished from that of endogenous fluorophores, and from that of most existing, commercially-available fluorescent probes. The compounds are well suited for use in "multiplexing" techniques. They exhibit clear isosbestic and isoemissive points, and have broad absorption and emission ranges.

48 IMMUNOREGULATORY COMPOUNDS AND DERIVATIVES AND METHODS OF TREATING DISEASES THEREWITH PCT/US2001/026697 2001-08-28 WO02018324A2 2002-03-07
Compounds are disclosed having the structure of Formula (I), where R<1>, R<3>, and R<4> are independently hydrogen or C1 to C4 alkyl, and R<2> is (II), where R<5> is selected from the group consisting of hydrogen and C1 to C4 alkyl, or (III), where R<6>, R<7> and R<8> are independently hydrogen or C1 to C4 alkyl; or the esters or pharmacologically acceptable salts thereof. Such compounds may be utilized for the prophylaxis or treatment of various diseases, particularly inflammatory conditions of the GI tract. Methods of treating inflammatory conditions of the GI tract such as inflammatory bowel disease using compounds having the following formula are also disclosed (IV), where R<9>, R<10> and R<11> are independently selected from the group consisting of hydrogen and C1 to C4 alkyl, and R<12> is selected from the group consisting of hydrogen and -C(O)R<13>, where R<13> is a C1 to C6 alkyl or an aryl group.
49 AZOPHENOLS AS ERG ONCOGENE INHIBITORS EP16845184.7 2016-09-09 EP3347001B1 2023-07-26 DOBI, Albert L.; DALGARD, Clifton; SRIVASTAVA, Shiv
50 ACYLHYDRAZONES FOR THE TREATMENT OF NEUROLOGICAL DISEASES EP19813064.3 2019-09-27 EP3858342A1 2021-08-04 PÉREZ FERNÁNDEZ, Ruth; CANAL MARTÍN, Andrea; SANCHEZ BARRENA, María José; MANSILLA APARICIO, Alicia

The present invention relates to a group of compounds with an acylhydrazone structural core having the capacity to modulate interaction between NCS-1 and Ric8a proteins involved in the process of regulating the number of synapses and the neurotransmitter release probability. These compounds are therefore useful for the treatment of neurological diseases in which the number of synapses is affected, such as Alzheimer's disease, Huntington's disease, or Parkinson's disease.

51 TUNABLE NITRIC OXIDE-RELEASING MACROMOLECULES HAVING MULTIPLE NITRIC OXIDE DONOR STRUCTURES EP12825927.2 2012-08-24 EP2748141B1 2017-12-06 SCHOENFISCH, Mark; LU, Yuan; STASKO, Nathan; BAO, Jian
52 TUNABLE NITRIC OXIDE-RELEASING MACROMOLECULES HAVING MULTIPLE NITRIC OXIDE DONOR STRUCTURES EP12825927.2 2012-08-24 EP2748141A4 2015-04-08 SCHOENFISCH, Mark; LU, Yuan; STASKO, Nathan; BAO, Jian
53 A REAGENT, A KIT, AND A METHOD FOR DETECTING AND IDENTIFYING A WIDE RANGE OF ILLICIT DRUGS EP08789821.9 2008-08-21 EP2200972A4 2013-05-29 AMISAR, Shai
54 Herstellung von Diazo-und Azoverbindungen EP88109835.4 1988-06-21 EP0297397A3 1991-08-21 Lorenz, Manfred, Dr.

Herstellung von Diazoverbindungen durch Diazogruppen­übertragung auf aktivierte Methylenverbindungen, dadurch gekennzeichnet, daß man ein Azidoformamidiniumsalz als Diazogruppenüberträger verwendet sowie Herstellung von Azoverbindungen auf diesem Wege.

55 Aromatische Säuren EP89810336.1 1989-05-01 EP0342157A2 1989-11-15 Chang, Jui Yoa, Dr.

Die Erfindung betrifft neue aromatische Säuren, insbesondere Verbindungen der Formel worin R₁ Niederalkyl darstellt, R₂ Niederalkyl ist, R₃ Wasserstoff, Carboxy oder Sulfo bedeutet, R₄ Carboxy oder Sulfo ist, G für eine gegebenenfalls substituierte 1,4-Phenylengruppe oder eine gegebenenfalls substituierte 1,4-Naphthylengruppe steht und worin entweder R₅ und R₆ gemeinsam für eine zusätzliche Bindung stehen und L ein Sauerstoff- oder ein Schwefelatom bedeutet oder worin R₅ Wasserstoff ist, R₆ Halogenmethyl bedeutet und L für ein Sauerstoffatom steht, und ihre Salze, die Verwen­dung der Verbindungen I und ihrer Salze, ein Verfahren zur Herstellung der Verbindungen I und ihrer Salze, in diesem Herstellungsverfahren verwendete Ausgangsstoffe und deren Salze, ein Verfahren zur Herstellung dieser Ausgangsstoffe und ihre Salze, eine Vorrichtung, in welcher die Verbindungen I und ihre Salze Verwendung finden, und ein Verfahren, in welchem diese Vorrichtung Verwendung findet. Die Verbindungen der Formel I können als Hilfsmittel bei der Untersuchung von Proteinen verwendet werden und sind in an sich bekannter Weise herstellbar.

56 Herstellung von Diazo-und Azoverbindungen EP88109835.4 1988-06-21 EP0297397A2 1989-01-04 Lorenz, Manfred, Dr.

Herstellung von Diazoverbindungen durch Diazogruppen­übertragung auf aktivierte Methylenverbindungen, dadurch gekennzeichnet, daß man ein Azidoformamidiniumsalz als Diazogruppenüberträger verwendet sowie Herstellung von Azoverbindungen auf diesem Wege.

57 Anti-inflammatory agents EP88300163.8 1988-01-11 EP0276065A1 1988-07-27 Bollinger, Nancy Grace; Goodson, Theodore, Jr.; Herron, David Kent

This invention provides benzene derivatives of the Formula I pharmaceutical formulations of those derivatives, and a method of using the derivatives for the treatment of inflammation in mammals.

58 AZOPHENOLS AS ERG ONCOGENE INHIBITORS EP16845184.7 2016-09-09 EP3347001A4 2019-05-08 DOBI, Albert L.; DALGARD, Clifton; SRIVASTAVA, Shiv
59 AZOPHENOLS AS ERG ONCOGENE INHIBITORS EP16845184.7 2016-09-09 EP3347001A1 2018-07-18 DOBI, Albert L.; DALGARD, Clifton; SRIVASTAVA, Shiv
60 PEPTIDE DEFORMYLASE INHIBITORS EP02748375.9 2002-03-01 EP1363873A4 2006-01-04 XIANG, JIA-NING; CHRISTENSEN, Siegfried, B.; LEE, Jinhwa; MERCER, Daniel, J.
Nobel PDF inhibitors and novel methods for their use are provided.
QQ群二维码
意见反馈